New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
10:00 EDTFUR, AEGR, RPTP, SWKS, MDVN, QSII, GWAY, WGP, LLNW, CERN, STAG, IDRA, AKAMOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Akamai (AKAM) initiated with a Neutral at Macquarie... Cerner (CERN) initiated with an Overweight at JPMorgan... Greenway Medical (GWAY) initiated with an Overweight at JPMorgan... Idera Pharmaceuticals (IDRA) initiated with an Overweight at Piper Jaffray... Limelight Networks (LLNW) initiated with a Neutral at Macquarie... Quality Systems (QSII) initiated with an Underweight at JPMorgan... STAG Industrial (STAG) initiated with a Market Perform at Wells Fargo... Western Gas Equity (WGP) initiated with a Buy at Citigroup... Winthrop Realty (FUR) initiated with a Market Perform at JMP Securities... Skyworks (SWKS) initiated with a Buy at Longbow... Aegerion (AEGR) initiated with a Buy at Janney Capital... Medivation (MDVN) initiated with a Buy at Janney Capital... Raptor Pharmaceuticals (RPTP) initiated with a Buy at Janney Capital.
News For AKAM;CERN;GWAY;IDRA;LLNW;QSII;STAG;WGP;FUR;SWKS;AEGR;MDVN;RPTP From The Last 14 Days
Check below for free stories on AKAM;CERN;GWAY;IDRA;LLNW;QSII;STAG;WGP;FUR;SWKS;AEGR;MDVN;RPTP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 15, 2014
10:00 EDTWGPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:00 EDTQSII, CERNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:50 EDTWGPWestern Gas Equity downgraded to Accumulate from Buy at Tudor Pickering
Subscribe for More Information
April 14, 2014
17:16 EDTMDVNUniversity of California files complaint against Medivation
Subscribe for More Information
17:12 EDTQSIIQuality Systems reinstated with a Market Perform at Raymond James
Raymond James reinstated coverage of Quality Systems with a Market Perform rating, up from its previous rating of Underperform.
16:55 EDTCERNCerner reinstated with an Outperform at Raymond James
Subscribe for More Information
07:06 EDTAKAMU.S. Geospatial Intelligence Foundation to hold a symposium
GEOINT 2013 Symposium, originally scheduled for October 2013, is being held in Tampa, Florida on April 14-17.
April 10, 2014
10:00 EDTAKAMOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:19 EDTAKAMAkamai upgraded to Buy from Neutral at B. Riley
Subscribe for More Information
06:00 EDTAKAMAkamai upgraded to Buy from Neutral at B. Riley
Subscribe for More Information
April 9, 2014
08:08 EDTAEGRAegerion initiates Phase 3 clinical trial for lomitapide in Japan
Subscribe for More Information
April 8, 2014
11:27 EDTAKAMOptions with increasing implied volatility: PBR AKAM WDAY EXPE
11:03 EDTAEGRPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
April 7, 2014
16:13 EDTIDRAIdera says preclinical data shows inhibition of lymphoma cells
Idera Pharmaceuticals presented new preclinical data demonstrating the ability of its Toll-like receptor antagonist, IMO-8400, to inhibit the survival and proliferation of B-cell lymphoma cells harboring the oncogenic MYD88 L265P genetic mutation. These data add to the research which supports the company’s efforts to develop IMO-8400 for the treatment of genetically defined forms of B-cell lymphoma. The data build upon reports from independent investigators and provide additional evidence that the MYD88 L265P mutation, which is present in certain B-cell lymphomas, results in over-activation of TLR7 and TLR9 mediated signaling. Idera has opened enrollment in a Phase 1/2 trial of IMO-8400 designed to evaluate IMO-8400’s safety, tolerability and potential clinical activity in patients with Waldenstrom’s macroglobulinemia who are refractory to prior therapies. The company anticipates that patient treatment in this trial will begin in Q2. Idera has also submitted a separate protocol to the U.S. FDA to conduct a Phase 1/2 trial in patients with DLBCL who harbor the MYD88 L265P mutation.
13:05 EDTSWKSAnalyst says semiconductor stocks attractive after decline
Subscribe for More Information
11:49 EDTAKAMOptions with increasing implied volatility: PBR AKAM HST L
Subscribe for More Information
08:16 EDTSWKSPullback in semiconductor stocks creates buying opportunity, says Sterne Agee
After many semiconductor stocks dropped significantly on Friday, Sterne Agee thinks that the group's fundamental mid to long-term outlook hasn't changed. Sterne Agee thinks the companies are poised to benefit from strong product cycles and earnings leverage. It is most upbeat on Micron (MU), NXP Semiconductors (NXPI), Avago (AVGO), Skyworks (SWKS), and SanDisk (SNDK). The firm keeps Buy ratings on all the stocks named.
07:44 EDTLLNWMarketo to hold a summit
Subscribe for More Information
April 4, 2014
07:06 EDTRPTPTransgenomic announces collaboration with Raptor Pharmaceuticals
Subscribe for More Information
April 3, 2014
08:27 EDTMDVNLeerink's biotech analyst holds a dinner meeting update
Biotech Analyst Liang holds an update from the AACR's Annual Meeting to discuss some of the presentations including PFE/AMGN's Palbociclib, PBYI/PFE's Neratinib, as well as other new agents for breast cancer from LLY, MDVN and CLDX, in San Diego on April 7 at 9 pm.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use